Wegovy users have fewer kidney-related health problems, analysis of Novo study finds

Novo Nordisk's (NOVOb.CO) Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.